Free Trial
NASDAQ:NAGE

Niagen Bioscience (NAGE) Stock Price, News & Analysis

Niagen Bioscience logo
$11.51 -0.21 (-1.79%)
As of 06/5/2025 04:00 PM Eastern

About Niagen Bioscience Stock (NASDAQ:NAGE)

Key Stats

Today's Range
$11.45
$11.80
50-Day Range
$5.42
$11.78
52-Week Range
$2.31
$12.07
Volume
632,420 shs
Average Volume
846,974 shs
Market Capitalization
$906.64 million
P/E Ratio
67.71
Dividend Yield
N/A
Price Target
$13.00
Consensus Rating
Buy

Company Overview

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Niagen Bioscience Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
17th Percentile Overall Score

NAGE MarketRank™: 

Niagen Bioscience scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Niagen Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Niagen Bioscience has only been the subject of 1 research reports in the past 90 days.

  • Read more about Niagen Bioscience's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Niagen Bioscience is 67.71, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.48.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Niagen Bioscience is 67.71, which means that it is trading at a more expensive P/E ratio than the Manufacturing sector average P/E ratio of about 22.63.

  • Short Interest

    There is no current short interest data available for NAGE.
  • Dividend Yield

    Niagen Bioscience does not currently pay a dividend.

  • Dividend Growth

    Niagen Bioscience does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for NAGE.
  • News Sentiment

    Niagen Bioscience has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Manufacturing companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Niagen Bioscience this week, compared to 3 articles on an average week.
  • Search Interest

    17 people have searched for NAGE on MarketBeat in the last 30 days. This is an increase of 55% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Niagen Bioscience to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Niagen Bioscience insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.39% of the stock of Niagen Bioscience is held by insiders.

  • Percentage Held by Institutions

    Only 15.41% of the stock of Niagen Bioscience is held by institutions.

  • Read more about Niagen Bioscience's insider trading history.
Receive NAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Niagen Bioscience and its competitors with MarketBeat's FREE daily newsletter.

NAGE Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
NAGE Niagen Bioscience, Inc.
Niagen Bioscience: Overbought After Rally
See More Headlines

NAGE Stock Analysis - Frequently Asked Questions

Niagen Bioscience's stock was trading at $5.48 at the start of the year. Since then, NAGE stock has increased by 110.0% and is now trading at $11.51.
View the best growth stocks for 2025 here
.

Shares of NAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Medicinal Chemicals
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NAGE
Previous Symbol
NASDAQ:NAGE
Web
N/A
Fax
N/A
Employees
120
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.00
High Stock Price Target
$13.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+12.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
67.71
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$107.93 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$906.64 million
Optionable
N/A
Beta
1.94
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:NAGE) was last updated on 6/6/2025 by MarketBeat.com Staff
From Our Partners